A Good enough reason for anyone to buy in.
The following was from a recent broker report.........
We value Admedus at $0.25 per share base case and $0.56 per share optimistic case. Our target price of $0.25 sits in the low point of our valuation range. We expect the market to re-rate Admedus as further clinical and pre-clinical data emerges and CardioCel gains commercial traction.
A Good enough reason for anyone to buy in. The following was...
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.31 |
Change
-0.240(1.29%) |
Mkt cap ! $351.9M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.20 | $159.7K | 8.611K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73 | $18.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.33 | 90 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |